Literature DB >> 15650218

Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1.

Xavier Carnec1, Lan Quan, William C Olson, Uriel Hazan, Tatjana Dragic.   

Abstract

CXCR4 is one of two physiologically relevant human immunodeficiency type 1 (HIV-1) entry coreceptors. Studies of CXCR4 mutants have not clearly identified the determinants of coreceptor function and specificity. We therefore used a panel of monoclonal antibodies to further elucidate CXCR4 expression, structure, and function. Our findings show the existence of conformational subpopulations of CXCR4 that are in equilibrium on the cell surface but are not cell type specific as previously reported. HIV-1 X4 isolates can interact with multiple CXCR4 conformations in order to gain entry into target cells.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15650218      PMCID： PMC544137          DOI： 10.1128/JVI.79.3.1930-1933.2005

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  24 in total

1.  CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue.

Authors:  M L Penn; J C Grivel; B Schramm; M A Goldsmith; L Margolis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

Review 2.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

Authors:  E A Berger; P M Murphy; J M Farber
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

3.  Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Authors:  W C Olson; G E Rabut; K A Nagashima; D N Tran; D J Anselma; S P Monard; J P Segal; D A Thompson; F Kajumo; Y Guo; J P Moore; P J Maddon; T Dragic
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.

Authors:  T Dragic; A Trkola; S W Lin; K A Nagashima; F Kajumo; L Zhao; W C Olson; L Wu; C R Mackay; G P Allaway; T P Sakmar; J P Moore; P J Maddon
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.

Authors:  Emmanuel G Cormier; Tatjana Dragic
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  CXCR4 sequences involved in coreceptor determination of human immunodeficiency virus type-1 tropism. Unmasking of activity with M-tropic Env glycoproteins.

Authors:  Z X Wang; J F Berson; T Y Zhang; Y H Cen; Y Sun; M Sharron; Z H Lu; S C Peiper
Journal:  J Biol Chem       Date:  1998-06-12       Impact factor: 5.157

7.  Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

Authors:  Fotini Tsamis; Svetlana Gavrilov; Francis Kajumo; Christoph Seibert; Shawn Kuhmann; Tom Ketas; Alexandra Trkola; Anadan Palani; John W Clader; Jayaram R Tagat; Stuart McCombie; Bahige Baroudy; John P Moore; Thomas P Sakmar; Tatjana Dragic
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

8.  Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100.

Authors:  B Labrosse; A Brelot; N Heveker; N Sol; D Schols; E De Clercq; M Alizon
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

9.  Use of murine CXCR-4 as a second receptor by some T-cell-tropic human immunodeficiency viruses.

Authors:  C Parolin; A Borsetti; H Choe; M Farzan; P Kolchinsky; M Heesen; Q Ma; C Gerard; G Palú; M E Dorf; T Springer; J Sodroski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

10.  Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.

Authors:  L Wu; G LaRosa; N Kassam; C J Gordon; H Heath; N Ruffing; H Chen; J Humblias; M Samson; M Parmentier; J P Moore; C R Mackay
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307
View more
  22 in total

1.  CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.

Authors:  Sven Jähnichen; Christophe Blanchetot; David Maussang; Maria Gonzalez-Pajuelo; Ken Y Chow; Leontien Bosch; Sindi De Vrieze; Benedikte Serruys; Hans Ulrichts; Wesly Vandevelde; Michael Saunders; Hans J De Haard; Dominique Schols; Rob Leurs; Peter Vanlandschoot; Theo Verrips; Martine J Smit
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

Review 2.  Therapeutic antibodies directed at G protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; Fiona H Marshall
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

3.  Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection.

Authors:  Royce A Wilkinson; Seth H Pincus; Kejing Song; Joyce B Shepard; Alan J Weaver; Mohamed E Labib; Martin Teintze
Journal:  Bioorg Med Chem Lett       Date:  2013-01-30       Impact factor: 2.823

4.  Mapping Interaction Sites on Human Chemokine Receptors by Deep Mutational Scanning.

Authors:  Jeremiah D Heredia; Jihye Park; Riley J Brubaker; Steven K Szymanski; Kevin S Gill; Erik Procko
Journal:  J Immunol       Date:  2018-04-20       Impact factor: 5.422

5.  Structural and Biological Characterizations of Novel High-Affinity Fluorescent Probes with Overlapped and Distinctive Binding Regions on CXCR4.

Authors:  Siyu Zhu; Qian Meng; Robert T Schooley; Jing An; Yan Xu; Ziwei Huang
Journal:  Molecules       Date:  2019-08-13       Impact factor: 4.411

6.  Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment.

Authors:  Catherine J Hutchings; Gabriella Cseke; Greg Osborne; Jeanette Woolard; Andrei Zhukov; Markus Koglin; Ali Jazayeri; Jahnavi Pandya-Pathak; Christopher J Langmead; Stephen J Hill; Malcolm Weir; Fiona H Marshall
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

Review 7.  Structural Analysis of Chemokine Receptor-Ligand Interactions.

Authors:  Marta Arimont; Shan-Liang Sun; Rob Leurs; Martine Smit; Iwan J P de Esch; Chris de Graaf
Journal:  J Med Chem       Date:  2017-03-10       Impact factor: 7.446

8.  Thermal stability of the human immunodeficiency virus type 1 (HIV-1) receptors, CD4 and CXCR4, reconstituted in proteoliposomes.

Authors:  Mikhail A Zhukovsky; Stéphane Basmaciogullari; Beatriz Pacheco; Liping Wang; Navid Madani; Hillel Haim; Joseph Sodroski
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

9.  Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection.

Authors:  Nina Thakkar; Vanessa Pirrone; Shendra Passic; Wei Zhu; Vladyslav Kholodovych; William Welsh; Robert F Rando; Mohamed E Labib; Brian Wigdahl; Fred C Krebs
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

10.  i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4.

Authors:  Katherine Griffiths; Olan Dolezal; Benjamin Cao; Susan K Nilsson; Heng B See; Kevin D G Pfleger; Michael Roche; Paul R Gorry; Andrew Pow; Katerina Viduka; Kevin Lim; Bernadine G C Lu; Denison H C Chang; Thomas Murray-Rust; Marc Kvansakul; Matthew A Perugini; Con Dogovski; Marcel Doerflinger; Yuan Zhang; Kathy Parisi; Joanne L Casey; Stewart D Nuttall; Michael Foley
Journal:  J Biol Chem       Date:  2016-04-01       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.